OncoMatch/Clinical Trials/NCT06553339
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Is NCT06553339 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Oral HS-10516 for von hippel lindau-deficient clear cell renal cell carcinoma.
Treatment: Oral HS-10516 — The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: hypoxia-induced factor inhibitor
Hypoxia-induced factor inhibitors
Cannot have received: traditional Chinese medicine indicated for tumors
Exception: within 2 weeks prior to the first dose of study treatment
Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment.
Cannot have received: cytotoxic chemotherapy
Exception: within 3 weeks before the first dose of study treatment
Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
Cannot have received: investigational drug
Exception: within 3 weeks before the first dose of study treatment
Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
Cannot have received: systematic anti-tumor therapy
Exception: within 3 weeks before the first dose of study treatment
Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
Cannot have received: colony-stimulating factor
Exception: within 4 weeks before the first dose of study treatment
Colony-stimulating factors (CSFs) within 4 weeks before the first dose of study treatment
Cannot have received: local radiotherapy
Exception: within 2 weeks prior to the first dose of study treatment
Local radiotherapy within 2 weeks prior to the first dose of study treatment
Cannot have received: bone marrow radiotherapy or large-area irradiation
Exception: more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment
more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment
Cannot have received: major surgery
Exception: within 4 weeks prior to the first dose of study treatment
Major surgery within 4 weeks prior to the first dose of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06553339 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hypoxia-induced factor inhibitor, traditional Chinese medicine indicated for tumors, cytotoxic chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages